Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.
News|Articles|February 4, 2025
FDA Updates in Urology: January 2025
Author(s)Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Advertisement
Advertisement
Welcome to Urology Times’ monthly US Food and Drug Administration (FDA) update! This month, key developments include advances in prostate cancer treatment, a new approach to bladder cancer therapy, and expanded indications for emerging urologic drugs. Plus, a novel testosterone assay is set to impact diagnostic testing.
Related to this article
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Sandip Prasad, MD, MPhil, discusses the evolving role of chemoablation in recurrent low-grade, intermediate-risk NMIBC, including patient selection and treatment considerations.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Advertisement
Advertisement